**Supplementary Table 1.** Full listing of included studies with 3xTg-AD mouse source details. Citation refers to the numerical citation listed in the Supplementary References. If stated, most studies cite the mouse background as 129/C57BL6. When stated, mice were typically commercially acquired from Jackson Laboratory or gifted from a colony originating from the LaFerla Laboratory (original place of invention of the 3xTg-AD mouse model). The mouse source field provides additional details transcribed from the corresponding article on the mouse source; many simply cite the LaFerla laboratory’s initial publications of the 3xTg-AD model in 2003 [1, 2].

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Citation** | **Year** | **129/C57BL6 Background** | **Acquired by Jackson Laboratory or LaFerla Laboratory** | **Mouse source** |
| [3] | 2008 | Yes | not stated | previously described by from 129/C57BL/6 background |
| [4] | 2011 | Yes | not stated | C57BL6/129SvJ background homozygous [1, 2] |
| [5] | 2015 | Yes | not stated | C57BL6/129 background [1, 2] |
| [6] | 2015 | Yes | not stated | the same genetic background (hybrid 129/C57BL6 background). The characterization of 3xTg-AD mice has been described previously [1, 2] |
| [7] | 2014 | not stated | not stated | not stated |
| [8] | 2013 | not stated | not stated | the characterization of 3xTg-AD mice has been described previously [1, 2] |
| [9] | 2013 | not stated | No | bred and maintained at the University of Southern California |
| [10] | 2010 | Yes | Yes | obtained from Frank LaFerla through Jackson Laboratory, 129/Sv x C57BL/6 |
| [11] | 2009 | not stated | not stated | hybrid C57BL6 background. |
| [12] | 2013 | not stated | not stated | not stated |
| [13] | 2014 | not stated | not stated | 3xTg-AD mice were generated as previously described [1, 2] |
| [14] | 2011 | not stated | not stated | not stated |
| [15] | 2014 | Yes | Yes | initially obtained from F.M. LaFerla through the Jackson Laboratory, a hybrid of 129/Sv and C57BL/6 |
| [16] | 2011 | not stated | Yes | transgenic mice were characterized and described by and generously provided by Frank Laferla |
| [17] | 2010 | not stated | Yes | transgenic mice were characterized and described by [1, 2] and generously provided by Frank Laferla |
| [18] | 2015 | not stated | not stated | not stated |
| [19] | 2015 | not stated | Yes | created in the laboratory by Dr. Frank LaFerla |
| [20] | 2014 | not stated | not stated | not stated |
| [21] | 2016 | Yes | not stated | 129/C57BL/6 |
| [22] | 2014 | not stated | Yes | Jackson Laboratory, Bar Harbor, ME |
| [23] | 2013 | not stated | Yes | Jackson Laboratory, Bar Harbor, ME |
| [24] | 2011 | not stated | not stated | previously described by [1, 2] |
| [25] | 2007 | not stated | not stated | not stated |
| [26] | 2016 | Yes | Yes | purchased from Jackson laboratory, previously described by [1, 2], 129/C57BL/6 |
| [27] | 2011 | not stated | not stated | not stated |
| [28] | 2014 | Yes | Yes | originally supplied by Frank LaFerla (Irvine, CA, USA) [1, 2], 129/C57BL6 |
| [29] | 2011 | Yes | not stated | mixed C57BL6/129svj background |
| [30] | 2013 | No | No | generated by Dr. LaFerla and acquired by the National Institute of Aging, backcrossed C57BL6 |
| [31] | 2014 | Yes | Yes | C57BL6/129sv background originally by Frank LaFerla and Salvadore Oddo |
| [32] | 2010 | not stated | not stated | the derivation and characterization of 3xTg-AD described elsewhere [1, 2], homozygous |
| [33] | 2014 | Yes | not stated | 129/C57BL/6 |
| [34] | 2011 | not stated | not stated | the derivation and characterization of 3xTg-AD described elsewhere [1, 2] |
| [35] | 2008 | not stated | No | homozygous mice from UCI-Alzheimer's disease research center (NIH/NIA P50 AG16573) |
| [36] | 2014 | not stated | Yes | Jackson Laboratory, Bar Harbor, ME, [1, 2] |
| [37] | 2010 | Yes | not stated | 129/C57BL/6 background described previously by [1, 2] |
| [38] | 2013 | Yes | No | C57BL/6/129S, bred and maintained at the University of Southern California |
| [39] | 2012 | not stated | Yes | bred using initial breeding pair from Dr. LaFerla |
| [40] | 2013 | not stated | not stated | not stated |
| [41] | 2013 | Yes | Yes | 129/C57BL/6, gift from Dr. Laferla |
| [42] | 2013 | not stated | not stated | not stated |
| [43] | 2014 | not stated | not stated | not stated |
| [44] | 2015 | not stated | not stated | homozygous 3xTg, [1, 2] |
| [45] | 2016 | not stated | not stated | homozygous 3xTg,  |
| [46] | 2015 | not stated | not stated | unidentified, cite [1, 2] |
| [47] | 2016 | not stated | not stated | unidentified, cite [1, 2] |
| [47] | 2014 | not stated | Yes | generated by dr. Frank LaFerla |
| [48] | 2013 | not stated | not stated | originally generated by [1, 2] |
| [49] | 2011 | not stated | not stated | not stated |
| [50] | 2012 | not stated | not stated | not stated |
| [51] | 2015 | not stated | Yes | bred using an initial 3xTg-AD breeding pair courtesy of Dr. Frank LaFerla' |
| [52] | 2015 | Yes | Yes | homozygous from LaFerla through Jacons Laboratory, hybrid of 129/Sv and C57BL/6 |
| [53] | 2015 | not stated | not stated | 129/C57BL/6 background |

**SUPPLEMENTARY REFERENCES**

[1] Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. *Neurobiol Aging* **24**, 1063-1070.

[2] Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* **39**, 409-421.

[3] Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM (2008) Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. *J Neurosci* **28**, 11500-11510.

[4] Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A, LaFerla FM (2011) Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. *Am J Pathol* **179**, 980-991.

[5] Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, LaFerla FM, Blurton-Jones M (2015) Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. *Hippocampus* **25**, 813-826.

[6] Baglietto-Vargas D, Chen Y, Suh D, Ager RR, Rodriguez-Ortiz CJ, Medeiros R, Myczek K, Green KN, Baram TZ, LaFerla FM (2015) Short-term modern life-like stress exacerbates Abeta-pathology and synapse loss in 3xTg-AD mice. *J Neurochem* **134**, 915-926.

[7] Baglietto-Vargas D, Kitazawa M, Le EJ, Estrada-Hernandez T, Rodriguez-Ortiz CJ, Medeiros R, Green KN, LaFerla FM (2014) Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition. *Neurobiol Dis* **62**, 407-415.

[8] Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN (2013) Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. *Biol Psychiatry* **74**, 357-366.

[9] Barron AM, Rosario ER, Elteriefi R, Pike CJ (2013) Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer's disease. *PLoS One* **8**, e78554.

[10] Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I (2010) Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice. *Acta Neuropathol* **120**, 605-621.

[11] Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. *Proc Natl Acad Sci U S A* **106**, 13594-13599.

[12] Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. *Cell Death Dis* **4**, e612.

[13] Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S (2014) Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. *Neurobiol Aging* **35**, 2726-2735.

[14] Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH, 3rd, Martin B, Maudsley S (2011) Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. *PLoS One* **6**, e21660.

[15] Chen Y, Liang Z, Tian Z, Blanchard J, Dai CL, Chalbot S, Iqbal K, Liu F, Gong CX (2014) Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. *Mol Neurobiol* **49**, 547-562.

[16] Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, Canzoniero LM, Ciavardelli D, Rizzarelli E, Sensi SL (2011) Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. *PLoS One* **6**, e17971.

[17] Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM, Sensi SL (2010) Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. *Cell Death Dis* **1**, e91.

[18] Dagher NN, Najafi AR, Kayala KM, Elmore MR, White TE, Medeiros R, West BL, Green KN (2015) Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. *J Neuroinflammation* **12**, 139.

[19] Dai CL, Chen X, Kazim SF, Liu F, Gong CX, Grundke-Iqbal I, Iqbal K (2015) Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. *J Neural Transm (Vienna)* **122**, 607-617.

[20] Di Meco A, Joshi YB, Pratico D (2014) Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. *Neurobiol Aging* **35**, 1813-1820.

[21] Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Medeiros R (2016) AF710B, a novel M1/sigma1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. *Neurodegener Dis* **16**, 95-110.

[22] Giuliani D, Bitto A, Galantucci M, Zaffe D, Ottani A, Irrera N, Neri L, Cavallini GM, Altavilla D, Botticelli AR, Squadrito F, Guarini S (2014) Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways. *Neurobiol Aging* **35**, 537-547.

[23] Giuliani D, Ottani A, Zaffe D, Galantucci M, Strinati F, Lodi R, Guarini S (2013) Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms. *Neurobiol Learn Mem* **104**, 82-91.

[24] Green KN, Khashwji H, Estrada T, Laferla FM (2011) ST101 induces a novel 17 kDa APP cleavage that precludes Abeta generation in vivo. *Ann Neurol* **69**, 831-844.

[25] Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP (2007) Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. *Neurobiol Dis* **26**, 212-220.

[26] Hu Y, Lai J, Wan B, Liu X, Zhang Y, Zhang J, Sun D, Ruan G, Liu E, Liu GP, Chen C, Wang DW (2016) Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice. *Neurotoxicology* **53**, 290-300.

[27] Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. *J Immunol* **187**, 6539-6549.

[28] Knight EM, Martins IV, Gumusgoz S, Allan SM, Lawrence CB (2014) High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. *Neurobiol Aging* **35**, 1821-1832.

[29] Majumder S, Richardson A, Strong R, Oddo S (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. *PLoS One* **6**, e25416.

[30] Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ (2013) Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease. *Curr Top Behav Neurosci* **15**, 313-340.

[31] Martin SA, Jameson CH, Allan SM, Lawrence CB (2014) Maternal high-fat diet worsens memory deficits in the triple-transgenic (3xTgAD) mouse model of Alzheimer's disease. *PLoS One* **9**, e99226.

[32] Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM (2010) Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. *Am J Pathol* **176**, 870-880.

[33] Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, Esbenshade TA, Bitner RS, Decker MW, LaFerla FM (2014) alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. *Am J Pathol* **184**, 520-529.

[34] Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. *Brain Pathol* **21**, 140-149.

[35] Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG (2008) Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. *PLoS One* **3**, e2124.

[36] Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, Smith MA, Zhu X, Casadesus G (2014) Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. *J Neurochem* **130**, 115-125.

[37] Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN (2010) Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. *J Alzheimers Dis* **21**, 527-542.

[38] Parrella E, Maxim T, Maialetti F, Zhang L, Wan J, Wei M, Cohen P, Fontana L, Longo VD (2013) Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model. *Aging Cell* **12**, 257-268.

[39] Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q, Peng Y, Eckenhoff MF, Wei H (2012) Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. *Neurosci Lett* **516**, 274-279.

[40] Rasool S, Martinez-Coria H, Milton S, Glabe CG (2013) Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice. *Mol Neurobiol* **48**, 931-940.

[41] Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG (2013) Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. *J Neurochem* **126**, 473-482.

[42] Ratia M, Gimenez-Llort L, Camps P, Munoz-Torrero D, Perez B, Clos MV, Badia A (2013) Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD). *Neurodegener Dis* **11**, 129-140.

[43] Revilla S, Ursulet S, Alvarez-Lopez MJ, Castro-Freire M, Perpina U, Garcia-Mesa Y, Bortolozzi A, Gimenez-Llort L, Kaliman P, Cristofol R, Sarkis C, Sanfeliu C (2014) Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. *CNS Neurosci Ther* **20**, 961-972.

[44] Sabogal-Guaqueta AM, Munoz-Manco JI, Ramirez-Pineda JR, Lamprea-Rodriguez M, Osorio E, Cardona-Gomez GP (2015) The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. *Neuropharmacology* **93**, 134-145.

[45] Sabogal-Guaqueta AM, Osorio E, Cardona-Gomez GP (2016) Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice. *Neuropharmacology* **102**, 111-120.

[46] Sandoval-Hernandez AG, Buitrago L, Moreno H, Cardona-Gomez GP, Arboleda G (2015) Role of Liver X Receptor in AD Pathophysiology. *PLoS One* **10**, e0145467.

[47] Sandoval-Hernandez AG, Hernandez HG, Restrepo A, Munoz JI, Bayon GF, Fernandez AF, Fraga MF, Cardona-Gomez GP, Arboleda H, Arboleda GH (2016) Liver X receptor agonist modifies the DNA methylation profile of synapse and neurogenesis-related genes in the triple transgenic mouse model of Alzheimer's disease. *J Mol Neurosci* **58**, 243-253.

[48] Sung YM, Lee T, Yoon H, DiBattista AM, Song JM, Sohn Y, Moffat EI, Turner RS, Jung M, Kim J, Hoe HS (2013) Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. *Exp Neurol* **239**, 192-201.

[49] Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM (2011) Inflammation induced by infection potentiates tau pathological features in transgenic mice. *Am J Pathol* **178**, 2811-2822.

[50] Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, Luo W, Li Y, Caracciolo L, Russo I, Barlati S, Ray B, Lahiri DK, Bosetti F, Greig NH, Rosi S (2012) Tumor necrosis factor-alpha synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. *J Neuroinflammation* **9**, 106.

[51] Wu Z, Yang B, Liu C, Liang G, Liu W, Pickup S, Meng Q, Tian Y, Li S, Eckenhoff MF, Wei H (2015) Long-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic mice. *Alzheimer Dis Assoc Disord* **29**, 184-191.

[52] Yu Y, Li X, Blanchard J, Li Y, Iqbal K, Liu F, Gong CX (2015) Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. *J Neural Transm (Vienna)* **122**, 593-606.

[53] Zumkehr J, Rodriguez-Ortiz CJ, Cheng D, Kieu Z, Wai T, Hawkins C, Kilian J, Lim SL, Medeiros R, Kitazawa M (2015) Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. *Neurobiol Aging* **36**, 2260-2271.